CoChat

The Impact of Body Composition on Outcomes in NSCLC Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review

Golban, Carina, Susa, Septimiu-Radu, Varga, Norberth-Istvan, Ivan, Cristiana-Smaranda, Schirta, Patricia Ortansa, Schirta, Nicolae Călin, Negru, Alina Gabriela, Saftescu, Sorin, Negru, Serban Mircea · 2025 · Cancers
Cited by 9

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background/Objectives: Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have become a standard in the treatment of all stages of non-small lung cancer. Beyond tumor-intrinsic biomarkers like PD-L1 expression, evidence points to the role of patient-related factors, such as body mass index, sarcopenia, and cachexia. These body composition parameters may reflect metabolic reserve or even immune competence and could help stratify outcomes in patients treated with PD-1 and PD-L1. This systematic review aims to evaluate the impact of body composition—specifically BMI, pretreatment weight loss, sarcopenia, and cachexia—on clinical outcomes such as progression-free and overall survival in NSCLC patients treated with immune checkpoint inhibitors. Methods: A systematic literature search was conducted across multiple databases including PubMed, Google Scholar, and Science Direct. We included full-text original research articles (1 January 2020–1 May 2025) reporting clinical outcomes of NSCLC patients treated with PD-1 or PD-L1 inhibitors, in relation to body composition factors (BMI, pretreatment weight loss, sarcopenia, cachexia). Eligible studies involved adults (>18 years) and included observational cohorts or controlled trials; animal or in vitro studies were excluded. Data extraction and risk of bias assessments were performed independently by two reviewers, with discrepancies being resolved through a third one. Results: From 12,358 records identified, 21 studies met the inclusion criteria. Most were retrospective cohorts assessing the impact of pre-treatment weight loss, cachexia, and sarcopenia on ICI outcomes in NSCLC. These factors consistently predicted poorer survival and response, while BMI alone showed limited prognostic value. Considerable heterogeneity in body composition definitions and outcome reporting was observed. Conclusions: Body composition—particularly weight loss, cachexia, and sarcopenia—significantly impacts survival and response in NSCLC patients treated with ICIs. These factors reflect immune–metabolic dysfunction that may impair treatment efficacy. BMI alone is insufficient; routine assessment of muscle mass and cachexia could improve risk stratification.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers17172765

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 69

  1. Araghi, 2023, Recent advances in non-small cell lung cancer targeted therapy; an update review, Cancer Cell Int., 23, 162, 10.1186/s12935-023-02990-y · DOI · Paper page
  2. Zhang, 2024, Regulatory T cells in immune checkpoint blockade antitumor therapy, Mol. Cancer, 23, 251, 10.1186/s12943-024-02156-y · DOI
  3. Gang, 2024, Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions, Cancer Lett., 604, 217241, 10.1016/j.canlet.2024.217241 · DOI
  4. Lin, 2024, Regulatory mechanisms of PD-1/PD-L1 in cancers, Mol. Cancer, 23, 108, 10.1186/s12943-024-02023-w · DOI · Paper page
  5. Han, 2020, PD-1/PD-L1 pathway: Current researches in cancer, Am. J. Cancer Res., 10, 727
  6. Jiang, 2019, Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape, Mol. Cancer, 18, 10, 10.1186/s12943-018-0928-4 · DOI · Paper page
  7. Ricciuti, 2022, Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab, J. Clin. Oncol., 40, 9043, 10.1200/JCO.2022.40.16_suppl.9043 · doi:10.1200/jco.2022.40.16_suppl.9043
  8. Velcheti, 2024, 5-Year Real-World Outcomes with Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC, Clin. Lung Cancer, 25, 502, 10.1016/j.cllc.2024.05.002 · DOI
  9. Qin, H., Yan, H., Chen, Y., Xu, Q., Huang, Z., Jiang, W., Wang, Z., Deng, L., Zhang, X., and Zhang, L. (2024). Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations. BMC Cancer, 24. · DOI
  10. Reck, 2024, Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial, Eur. J. Cancer, 211, 114296, 10.1016/j.ejca.2024.114296 · DOI
  11. Ma, W., Shi, Q., Zhang, L., Qiu, Z., Kuang, T., Zhao, K., and Wang, W. (2024). Impact of baseline body composition on prognostic outcomes in urological malignancies treated with immunotherapy: A pooled analysis of 10 retrospective studies. BMC Cancer, 24. · DOI
  12. Kuang, T., Zhang, L., Qiu, Z., Zhang, Y., and Wang, W. (2023). Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy. Front. Immunol., 14. · DOI
  13. Ishihara, 2024, Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma, Urol. Oncol. Semin. Orig. Investig., 42, 291.e27
  14. da Fonseca, G.W.P., Farkas, J., Dora, E., von Haehling, S., and Lainscak, M. (2020). Cancer Cachexia and Related Metabolic Dysfunction. Int. J. Mol. Sci., 21. · DOI
  15. Baracos, 2014, Functional body composition and related aspects in research on obesity and cachexia: Report on the 12th Stock Conference held on 6 and 7 September 2013 in Hamburg, Germany, Obes. Rev., 15, 640, 10.1111/obr.12187 · DOI
  16. Rey, 2025, Relationship between muscular mass, inflammatory status, tumor metabolic activity and oral intake in head and neck cancer at the outset of management, Clin. Nutr. ESPEN, 66, 411, 10.1016/j.clnesp.2025.01.052 · DOI
  17. Dong, 2020, Identifying sarcopenia in advanced non-small cell lung cancer patients using skeletal muscle CT radiomics and machine learning, Thorac. Cancer, 11, 2650, 10.1111/1759-7714.13598 · DOI · Paper page
  18. Solomon, 2022, The prevalence of sarcopenia amongst non-small cell lung cancer patients, assessed using computed tomography, prior to treatment in a South African setting, S. Afr. J. Oncol., 6, 7
  19. Hakozaki, T., Nolin-Lapalme, A., Kogawa, M., Okuma, Y., Nakamura, S., Moreau-Amaru, D., Tamura, T., Hosomi, Y., Takeyama, H., and Richard, C. (2022). Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis. Cancers, 14. · DOI
  20. Jensen, 2023, Sarcopenia and loss of muscle mass in patients with lung cancer undergoing chemotherapy treatment: A systematic review and meta-analysis, Acta Oncol., 62, 318, 10.1080/0284186X.2023.2180660 · DOI
  21. Katsui, K., Ogata, T., Sugiyama, S., Yoshio, K., Kuroda, M., Hiraki, T., Kiura, K., Maeda, Y., Toyooka, S., and Kanazawa, S. (2021). Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: A retrospective analysis. Sci. Rep., 11. · DOI
  22. Yue, 2024, Understanding cachexia and its impact on lung cancer and beyond, Chin. Med J. - Pulm. Crit. Care Med., 2, 95, 10.1016/j.pccm.2024.02.003 · DOI
  23. Zhang, T., Li, S., Chang, J., Qin, Y., and Li, C. (2023). Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. BMC Cancer, 23. · DOI
  24. Assumpção, J.A.F., Pasquarelli-Do-Nascimento, G., Duarte, M.S.V., Bonamino, M.H., and Magalhães, K.G. (2022). The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy. J. Biomed. Sci., 29. · DOI
  25. Cortellini, 2020, Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: A multicenter study with external validation, J. Immunother. Cancer, 8, e001403, 10.1136/jitc-2020-001403 · DOI
  26. Wang, 2020, Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis, Int. Immunopharmacol., 88, 106907, 10.1016/j.intimp.2020.106907 · DOI
  27. Roch, 2020, Cachexia-sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors, Lung Cancer, 143, 19, 10.1016/j.lungcan.2020.03.003 · DOI
  28. Cohen, 2024, Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer, Curr. Oncol., 31, 7379, 10.3390/curroncol31110544 · DOI
  29. Vick, 2024, Potential roles of sex-linked differences in obesity and cancer immunotherapy: Revisiting the obesity paradox, npj Metab. Health Dis., 2, 5, 10.1038/s44324-024-00007-4 · DOI
  30. Ishida, Y., Maeda, K., Yamanaka, Y., Matsuyama, R., Kato, R., Yamaguchi, M., Nonogaki, T., Shimizu, A., Ueshima, J., and Murotani, K. (2020). Formula for the Cross-Sectional Area of the Muscles of the Third Lumbar Vertebra Level from the Twelfth Thoracic Vertebra Level Slice on Computed Tomography. Geriatrics, 5. · DOI · Paper page
  31. Fearon, 2011, Definition and classification of cancer cachexia: An international consensus, Lancet Oncol., 12, 489, 10.1016/S1470-2045(10)70218-7 · DOI · Paper page
  32. Tenuta, M., Gelibter, A., Pandozzi, C., Sirgiovanni, G., Campolo, F., Venneri, M.A., Caponnetto, S., Cortesi, E., Marchetti, P., and Isidori, A.M. (2021). Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study. Cancers, 13. · DOI
  33. Chaunzwa, 2024, Body Composition in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy, JAMA Oncol., 10, 773, 10.1001/jamaoncol.2024.1120 · DOI · Paper page
  34. Minami, 2020, Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients with Advanced Non-Small Cell Lung Cancer, World J. Oncol., 11, 9, 10.14740/wjon1225 · DOI
  35. Miyawaki, 2020, Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients with Advanced NSCLC, JTO Clin. Res. Rep., 1, 100020
  36. Nishioka, 2021, Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer, Cancer Med., 10, 247, 10.1002/cam4.3631 · DOI
  37. Takada, 2021, Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors, J. Cancer Res. Clin. Oncol., 146, 1217, 10.1007/s00432-020-03146-5 · DOI
  38. Wang, 2021, Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy, Ann. Transl. Med., 9, 1801, 10.21037/atm-21-6578 · DOI
  39. Miyawaki, 2022, Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer, Support. Care Cancer, 30, 1633
  40. Liu, Z., Diao, Y., and Li, X. (2022). Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors. BMC Cancer, 22. · DOI
  41. Jin, J., Visina, J., Burns, T.F., Diergaarde, B., and Stabile, L.P. (2023). Male sex and pretreatment weight loss are associated with poor outcome in patients with advanced non-small cell lung cancer treated with immunotherapy: A retrospective study. Sci. Rep., 13. · DOI
  42. Lee, 2023, Obesity paradox in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy, J. Cachex- Sarcopenia Muscle, 14, 2898, 10.1002/jcsm.13367 · DOI
  43. Matsuo, 2023, Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors, Thorac. Cancer, 14, 1362, 10.1111/1759-7714.14881 · DOI
  44. Murata, 2023, Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors, Cancer Med., 12, 19471, 10.1002/cam4.6549 · DOI
  45. Tanimura, K., Takeda, T., Yoshimura, A., Honda, R., Goda, S., Shiotsu, S., Fukui, M., Chihara, Y., Uryu, K., and Takei, S. (2023). Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study. Cancers, 15. · DOI
  46. Kawachi, 2025, Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy, OncoImmunology, 14, 2442116, 10.1080/2162402X.2024.2442116 · DOI
  47. Xue, D., Li, N., Yang, J., Men, K., Li, L., Jiang, H., Zhao, X., Zhang, S., and Chen, X. (2024). Sarcopenia predicts immune-related adverse events due to anti-PD-1/PD-L1 therapy in patients with advanced lung cancer. Front. Oncol., 14. · DOI
  48. Kuno, H., Nishioka, N., Yamada, T., Kunimatsu, Y., Yoshimura, A., Hirai, S., Futamura, S., Masui, T., Egami, M., and Chihara, Y. (2024). The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study. Cancers, 16. · DOI
  49. Rounis, 2021, Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: Results from a prospective, observational study, Transl. Lung Cancer Res., 10, 3538, 10.21037/tlcr-21-460 · DOI
  50. Antoun, 2023, Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle, Eur. J. Cancer, 178, 49, 10.1016/j.ejca.2022.10.013 · DOI
  51. Madeddu, C., Busquets, S., Donisi, C., Lai, E., Pretta, A., López-Soriano, F.J., Argilés, J.M., Scartozzi, M., and Macciò, A. (2023). Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. Cancers, 15. · DOI
  52. Chen, 2021, TNF in the era of immune checkpoint inhibitors: Friend or foe?, Nat. Rev. Rheumatol., 17, 213, 10.1038/s41584-021-00584-4 · DOI
  53. Huseni, 2023, CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy, Cell Rep. Med., 4, 100878, 10.1016/j.xcrm.2022.100878 · DOI · Paper page
  54. Stemmler, 2019, Therapeutic strategies against cancer cachexia, Eur. J. Transl. Myol., 29, 7960
  55. Ma, S., Zhao, G., Sui, S., Chen, X., Wu, L., Wang, T., Xu, W., Lu, Z., Wang, A., and Wu, X. (2025). Tumor microenvironment and immune-related myositis: Addressing muscle wasting in cancer immunotherapy. Front. Immunol., 16. · DOI
  56. VanderVeen, B.N., Murphy, E.A., and Carson, J.A. (2020). The Impact of Immune Cells on the Skeletal Muscle Microenvironment During Cancer Cachexia. Front. Physiol., 11. · DOI
  57. Ferrer, 2023, Cachexia: A systemic consequence of progressive, unresolved disease, Cell, 186, 1824, 10.1016/j.cell.2023.03.028 · DOI · Paper page
  58. Bye, 2017, Muscle mass and association to quality of life in non-small cell lung cancer patients, J. Cachex-Sarcopenia Muscle, 8, 759, 10.1002/jcsm.12206 · DOI
  59. Cole, 2018, The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention, JCSM Clin. Rep., 3, e00065
  60. Nakamura, 2018, Sarcopenia in Resected NSCLC: Effect on Postoperative Outcomes, J. Thorac. Oncol., 13, 895, 10.1016/j.jtho.2018.04.035 · DOI · Paper page
  61. Zhang, 2024, Harnessing immunomodulation to combat sarcopenia: Current insights and possible approaches, Immun. Ageing, 21, 55, 10.1186/s12979-024-00458-9 · DOI
  62. Zanetti, M., Cappellari, G.G., Barazzoni, R., and Sanson, G. (2020). The Impact of Protein Supplementation Targeted at Improving Muscle Mass on Strength in Cancer Patients: A Scoping Review. Nutrients, 12. · DOI
  63. Deng, 2021, Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis, Nutrition, 90, 111345, 10.1016/j.nut.2021.111345 · DOI
  64. Shepshelovich, 2019, Body Mass Index (BMI), BMI Change, and Overall Survival in Patients with SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium, J. Thorac. Oncol., 14, 1594, 10.1016/j.jtho.2019.05.031 · DOI
  65. Nitsche, L.J., Mukherjee, S., Cheruvu, K., Krabak, C., Rachala, R., Ratnakaram, K., Sharma, P., Singh, M., and Yendamuri, S. (2022). Exploring the Impact of the Obesity Paradox on Lung Cancer and Other Malignancies. Cancers, 14. · DOI
  66. Vedire, 2023, Obesity and lung cancer—A narrative review, J. Thorac. Dis., 15, 2806, 10.21037/jtd-22-1835 · DOI
  67. Rupert, 2021, Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia, J. Exp. Med., 218, e20190450, 10.1084/jem.20190450 · DOI · Paper page
  68. Shanks, 2025, BMI or not to BMI? debating the value of body mass index as a measure of health in adults, Int. J. Behav. Nutr. Phys. Act., 22, 23, 10.1186/s12966-025-01719-6 · DOI
  69. Palumbo, 2025, Validity of non-traditional measures of obesity compared to total body fat across the life course: A systematic review and meta-analysis, Obes. Rev., 26, e13894, 10.1111/obr.13894 · DOI

Metadata

Authors
Golban, C., Susa, S.-R., Varga, N.-I., Ivan, C.-S., Schirta, P. O., Schirta, N. C., Negru, A. G., Saftescu, S., & Negru, S. M.
Affiliations
  • Doctoral School, Department of General Medicine, “Victor Babes” University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
  • Department of General Medicine, “Victor Babeş” University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
  • Department of Internal Medicine, University Hospital of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland
  • Department of Internal Medicine, Medzentrum Pfungen Aerztehaus, Riedäckerstrasse 5, 8422 Pfungen, Switzerland
  • Department of Cardiology, “Victor Babeș” University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timișoara, Romania
  • Department of Oncology, Faculty of Medicine, “Victor Babeş” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
Venue
Cancers
Publisher
MDPI AG
Published
2025-08-25
Volume
17
Issue
17
Pages
2765
ISSN
2072-6694
Cited by
9
References
2
Language
en
Funders
“Victor Babes” University of Medicine and Pharmacy, Timișoara

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Impact of Body Composition on Outcomes in NSCLC Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review. https://app.cochat.ai/papers/10.3390/cancers17172765
The paper
Golban, C., Susa, S.-R., Varga, N.-I., Ivan, C.-S., Schirta, P. O., Schirta, N. C., Negru, A. G., Saftescu, S., & Negru, S. M. (2025). The Impact of Body Composition on Outcomes in NSCLC Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers. https://doi.org/10.3390/cancers17172765

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.